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Abstract
Background: Salmonella spp. with reduced susceptibility to fluoroquinolones have higher than usual MICs
to these agents but are still considered "susceptible" by NCCLS criteria. Delayed treatment response to
fluoroquinolones has been noted, especially in cases of enteric fever due to such strains. We reviewed the
ciprofloxacin susceptibility and clinical outcome of our recent enteric fever cases.
Methods: Salmonella enterica Serotype Typhi (S. Typhi) and Serotype Paratyphi (S. Paratyphi) blood
culture isolates (1998–2002) were tested against nalidixic acid by disk diffusion (DD) and agar dilution
(AD) and to ciprofloxacin by AD using NCCLS methods and interpretive criteria. Reduced
fluoroquinolone susceptibility was defined as a ciprofloxacin MIC of 0.125–1.0 mg/L. The clinical records
of patients treated with ciprofloxacin for isolates with reduced fluoroquinolone susceptibility were
reviewed.
Results:  Seven of 21 (33%) S. Typhi and S. Paratyphi isolates had reduced susceptibility to
fluoroquinolones (MIC range 0.125–0.5 mg/L). All 7 were nalidixic acid resistant by DD (no zone) and by
AD (MIC 128- >512 mg/L). The other 14 isolates were nalidixic acid susceptible and fully susceptible to
ciprofloxacin (MIC range 0.015–0.03 mg/L).
Five of the 7 cases were treated initially with oral ciprofloxacin. One patient remained febrile on IV
ciprofloxacin until cefotaxime was added, with fever recurrence when cefotaxime was discontinued. Two
continued on oral or IV ciprofloxacin alone but had prolonged fevers of 9–10 days duration, one was
switched to IV beta-lactam therapy after remaining febrile for 3 days on oral/IV ciprofloxacin and one was
treated successfully with oral ciprofloxacin. Four of the 5 required hospitalization.
Conclusions: Our cases provide further evidence that reduced fluoroquinolone susceptibility of S. Typhi
and S. Paratyphi is clinically significant. Laboratories should test extra-intestinal Salmonella spp. for reduced
fluoroquinolone susceptibility.
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Background
Salmonella enterica Serotype Typhi (S. Typhi) and Serotype
Paratyphi (S. Paratyphi) with reduced susceptibility to
fluoroquinolones are common in India and Southeast
Asia [1]. Such isolates have elevated minimum inhibitory
concentrations (MICs) to ciprofloxacin and other fluoro-
quinolones, although they are still considered "suscepti-
ble" using current National Committee for Clinical
Laboratory Standards (NCCLS) interpretive criteria [2].
Reduced susceptibility to fluoroquinolones most often
arises from point mutations in the quinolone resistance
determining region (QRDR) of the gyrA  gene which
encodes the A subunit of DNA gyrase. These mutations
lead to resistance to nalidixic acid, a quinolone, and resist-
ance to this agent can thus be used as an indicator of
reduced fluoroquinolone susceptibility [3].
Although the mechanisms of resistance have been
defined, there is still little information on the clinical sig-
nificance of reduced susceptibility to fluoroquinolones in
Salmonella. Limited published data suggest that treatment
of these infections with a fluoroquinolone may result in a
delay in clinical response and possibly treatment failure
[2].
As a result of this clinical data, NCCLS currently recom-
mends testing of extra-intestinal Salmonella  isolates for
nalidixic acid resistance as a marker for reduced fluoroqui-
nolone susceptibility [4]. Others have suggested a re-eval-
uation of the current fluoroquinolone MIC breakpoints
for Salmonella [2] while some recommend differentiating
between "low level resistance" (MICs of 0.125 – 1.0 mg/
L) and "high level resistance" (MICs >1.0 mg/L) [5].
A poor response to ciprofloxacin therapy in a patient with
typhoid fever at our hospital prompted us to review retro-
spectively the ciprofloxacin MICs and clinical outcomes of
other enteric fever cases that were treated with a fluoroqui-
nolone.
Methods
We tested 21 S. Typhi and S. Paratyphi blood culture iso-
lates recovered from patients at The Ottawa Hospital and
The Children's Hospital of Eastern Ontario between
1998–2002. Susceptibility testing was performed using
NCCLS methods and interpretive criteria [4,6,7]. Disk
Diffusion testing was performed using nalidixic acid (30
µg), ampicillin (10 µg), trimethoprim-sulfamethoxazole
(1.25 µg/23.75 µg), and chloramphenicol (30 µg) disks
(Oxoid, U.K.) on Mueller-Hinton agar plates (PML Micro-
biologicals, Mississauga, ON). MICs to nalidixic acid
(Sigma-Aldrich, St-Louis, MO) and ciprofloxacin (Bayer
Inc.) were determined by agar dilution using Mueller-Hin-
ton agar (Becton Dickinson and Company, Sparks, MD).
Reduced susceptibility to fluoroquinolones was defined
as a ciprofloxacin MIC of 0.125–1.0 mg/L [3].
We sequenced the QRDR region of the gyrA gene for all
isolates with reduced susceptibility to fluoroquinolones
to detect nucleotide mutations. PCR amplification and
DNA sequencing was performed using primers [8] and
conditions previously described [9]. Sequencing was per-
formed by the Ottawa Genome Centre DNA Sequencing
Institute using the Big Dye Terminator v 3.1 method.
Sequences were compared to the gyrA  sequence of the
fully susceptible S.  Typhimurium NCTC 74 (accession
number X78977, EMBL GenBank database) [8] and to 3
fully susceptible S. Typhi isolates.
Pulsed field gel electrophoresis (PFGE) was performed on
isolates with reduced susceptibility to fluoroquinolone
using XbaI. Medical records of patients who were treated
with ciprofloxacin for infections due to isolates with
reduced fluoroquinolone susceptibility were reviewed to
determine clinical outcomes.
Results
Laboratory
Seven of 21 isolates or 33% (4 of 12 S. Typhi and 3 of 9 S.
Paratyphi) were nalidixic acid resistant by disk diffusion,
all with no zones of inhibition. These isolates were all
nalidixic acid resistant with an MIC range of 128->512
mg/L, and demonstrated reduced susceptibility to fluoro-
quinolones (ciprofloxacin MIC range 0.125–0.5 mg/L).
The 14 nalidixic acid susceptible isolates by disk diffusion
(zone size range 20–25 mm) were also susceptible by agar
dilution (MIC range 2–4 mg/L), and none had reduced
susceptibility to fluoroquinolones (ciprofloxacin MIC
range 0.015–0.03 mg/L). Multidrug resistance was identi-
fied in 5 of 21 isolates (24%) with resistance to ampicil-
lin, trimethoprim-sulfamethoxazole, and
chloramphenicol.
All 7 isolates with reduced susceptibility to fluoroqui-
nolones had nucleotide point mutations in the gyrA gene
that resulted in amino acid substitutions: 5 had a Ser83 to
Phe change, one had a Ser83 to Tyr change, and one had
an Asp87 to Asn change.
PFGE of the 7 resistant isolates showed 3 of 4 S. Typhi to
have identical patterns. These 3 strains were also multid-
rug resistant to ampicillin, trimethoprim-sulfamethoxa-
zole and chloramphenicol. The fourth strain, which was
susceptible to ampicillin, trimethoprim-sulfamethoxa-
zole and chloramphenicol, was a closely related strain (2
band difference). Two of 3 S.  Paratyphi had identical
PFGE patterns, with the third being possibly related (4
band difference) [10]. All 3 isolates of S. Paratyphi were
susceptible to the other antibiotics tested.BMC Infectious Diseases 2004, 4:36 http://www.biomedcentral.com/1471-2334/4/36
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Clinical (Table 1- see Additional file 1)
Infections with the 7 isolates with reduced susceptibility
to fluoroquinolones were all acquired in the Indian sub-
continent. Five of the 7 patients with infections due to
these isolates were treated initially with ciprofloxacin. The
clinical and microbiological findings for these 5 are sum-
marized in Table 1 (see Additional file 1). S. Typhi isolates
from cases 1, 3 and 4 were also resistant to ampicillin, tri-
methoprim-sulfamethoxazole and chloramphenicol. The
Salmonella isolates from the other 2 cases were susceptible
to these antibiotics. Of note, 3 of 4 patients with S. Typhi
had fever durations well in excess of the expected 95%
upper confidence limit of 3.9 days found in a pooled anal-
ysis of multiple studies. These studies involved patients
with predominantly nalidixic acid susceptible S. Typhi
who were treated with fluoroquinolones [1].
The patient infected with S. Paratyphi with reduced sus-
ceptibility to fluoroquinolone was judged to be failing
ciprofloxacin, since there was no clinical improvement
after 3 days of treatment. Although fever of this duration
is common, patients with enteric fever given fluoroqui-
nolones may show some clinical improvement by this
time. Three days with no amelioration of symptoms has
been used as indicator of a poor response to therapy in
some studies [11,12]. Thus, this patient possibly may have
had a poor response to therapy due to the elevated cipro-
floxacin MIC.
None of the 5 had a recurrence of bacteremia after antibi-
otics were discontinued, and none died.
Discussion
Fluoroquinolones have been considered the treatment of
choice for enteric fever. As noted, a mean fever clearance
time of only 3.9 days (for predominantly nalidixic acid-
susceptible strains) has been reported, which is shorter
than for other agents [1]. Calculated clinical and micro-
biologic failure rates of 2.1% and 0.4%, respectively, are
also low in comparison to other antibiotics [1]. Relapse
rates (1.2%) and fecal carriage rates (1.5%) have also been
lower than for the traditional drugs, trimethoprim-sul-
famethoxazole and chloramphenicol.
However, reduced susceptibility to fluoroquinolones
jeopardises the usefulness of these agents. It is now seen
frequently in S. Typhi and S. Paratyphi isolates acquired in
the Indian subcontinent and Southeast Asia [1], where
common clones appear to be circulating. In fact, the com-
mon PFGE profile of 3 of our S. Typhi isolates with
reduced susceptibility to fluoroquinolones appears to be
the same as that described for S. Typhi strains from India,
Pakistan, Bangladesh, and Tajikistan [13]. The gyrA point
mutations in our isolates have also been previously
described in isolates from these countries [1,3].
Several lines of evidence support the clinical significance
of elevated fluoroquinolone MICs in Salmonella  spp.,
including case reports, animal experiments, and pharma-
codynamic modelling [2]. In a report of patients treated
with short courses of oral ofloxacin [11], the median time
to fever clearance was greater for patients infected with
nalidixic acid resistant S. Typhi than for those with nalid-
ixic acid susceptible strains. In addition, one third of nali-
dixic acid resistant infections required re-treatment vs.
0.8% of infections due to susceptible strains. The authors
concluded that short courses (less than 5 days) of oral
fluoroquinolone therapy should not be used for treating
nalidixic acid resistant isolates. Our small series adds to
the evidence that there is a delayed clinical response to
fluoroquinolone therapy in this setting, and demonstrates
that fever may be prolonged even with long courses of
fluoroquinolone therapy, and even when given parenter-
ally in some cases.
Until results from randomized controlled trials of enteric
fever due to strains with reduced susceptibility to fluoro-
quinolones are available, the best treatment regimen is
uncertain. Current options include higher dose and
longer duration of fluoroquinolones, 3rd generation
cephalosporins and azithromycin, either alone or in com-
bination [1]. If susceptible, agents such as ampicillin, tri-
methoprim-sulfamethoxazole, and chloramphenicol may
also be considered, but rates of resistance to these agents
are generally too high to recommend as first-line empiric
therapies [1]. In our series, resistance to all these agents
was high among the isolates with reduced fluoroqui-
nolone susceptibility (3 of 7 or 43%).
When fluoroquinolones are given, it is important to bear
in mind that two pharmacokinetic/pharmacodynamic
ratios are predictive of successful treatment with these
agents [2]. These are the ratio of peak serum antimicrobial
level to the MIC, and the ratio of the 24-hour area under
the serum concentration-versus-time curve to the MIC
(AUC/MIC). Higher dosing will maximize these ratios,
and thus when oral ciprofloxacin is given for suspected
enteric fever, use of 750 mg rather than 500 mg bid seems
logical.
It is important that microbiology laboratories have proce-
dures to detect Salmonella strains that have reduced sus-
ceptibility to fluoroquinolones. The current NCCLS
guidelines (2004) recommend that all extra-intestinal iso-
lates of Salmonella be tested for resistance to nalidixic acid
in order to detect reduced fluoroquinolone susceptibility
[4]. In addition, it is recommended that physicians be
informed that isolates that test fluoroquinolone "suscep-
tible" but nalidixic acid resistant may not be eradicated
with fluoroquinolone therapy.BMC Infectious Diseases 2004, 4:36 http://www.biomedcentral.com/1471-2334/4/36
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There have also been suggestions to change the NCCLS
breakpoints to reflect the risk of treatment failure of Sal-
monella spp. with reduced susceptibility to fluoroquinolo-
nes [1]. This is clearly a difficult decision, since
fluoroquinolones have previously been the most active
antibiotic class for treatment of enteric fever. Some
patients with these isolates may do poorly on short
courses and lower doses of fluoroquinolones but poten-
tially could respond adequately to higher doses and
longer durations of treatment. Rather than reclassifying all
isolates with reduced susceptibility to fluoroquinolones
as being resistant to ciprofloxacin, others have recom-
mended differentiating between low-level (MIC of 0.125
– 1.0 mg/L) and high-level (MIC >1.0 mg/L) ciprofloxacin
resistance based on the MIC range [5].
It is not completely clear at present which of these is the
optimal approach for laboratory detection of Salmonella
spp. with reduced fluoroquinolone susceptibility. Not all
laboratories routinely perform MICs and many rely on
commercially-available automated susceptibility meth-
ods that cannot currently detect reduced fluoroquinolone
susceptibility. The current NCCLS recommendations to
test for nalidixic resistance are easy to implement for rou-
tine testing but may have reduced specificity [3]. Labora-
tories need to decide which approach is best for their
workflow and available resources.
Conclusions
Given the accumulating evidence, including our own clin-
ical experience, enteric fever due to Salmonella spp. with
reduced susceptibility to fluoroquinolones is clinically
significant. It is important that laboratories test S. Typhi
and S. Paratyphi, as well as other extra-intestinal Salmo-
nella isolates, for reduced susceptibility to fluoroquinolo-
nes.
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